Cancer research is a major area of excellence in our faculty. We are the founding partner of the CRUK City of London Centre, which is revolutionising the way cancer research is conducted in London.
Using our scale to define niche subtypes through meticulously phenotyped cohorts that accelerate clinical trials and outcomes and enable research for unmet need in adult and paediatric oncology. We administer several programmes from Cancer Research UK and multiple projects and fellowships, including our Barts Cancer Centre which received £10 million an official CRUK Centre. The funds support research facilities and training programmes, aiming to accelerate development and adoption of innovative treatments and diagnostics. Our Experimental Cancer Medicine Centre focuses on the treatment of cancers with unmet need, including pancreatic, oesophageal and mesothelioma.
Our Centre for Cancer Prevention conducts research into the prevention of cancer with particular focus on preventive therapy and screening. Major successes include the impact of the IBIS-II trial, which studied almost 4,000 postmenopausal women at high risk of breast cancer, finding that those treated with anastrozole were 53% less likely to develop breast cancer, and that the drug was more effective than tamoxifen, with fewer side effects.
Brain tumour research
We have renewed our Brain Tumour Research Centre of Excellence with £3 million and a further £1.6m of funding from the Brain Tumour Research charity. Our aim is to elucidate the epigenome of glioblastoma multiforme, the most common and aggressive type of malignant brain tumour. We have international leadership in a rare form of hereditary brain tumour (in familial isolated pituitary adenoma), for which we have identified the gene alteration and developed assays to enable intervention.
Squamous cell cancer
We have built on our world leadership in applied and translational research in skin cancer, to form the cross-Institute Barts Centre for Squamous Cancer with a research focus on epithelial cancer including non-melanoma skin cancer, esophageal as well as head and neck cancer.